It is possible that the main title of the report Primary Gastric Lymphoma is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Updated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 2).
Added text to state that follicular lymphoma in situ and primary follicular lymphoma of the duodenum are particularly indolent variants that rarely progress and rarely require therapy (cited Schmatz et al. and Jegalian et al. as references 17 and 18, respectively).
Revised text to state that myeloablative therapy with autologous or allogeneic hematopoietic stem cell support is under clinical evaluation (cited Kyriakou et al. as reference 48).
Added Nakamura et al. as reference 62.
Added Kempf et al. as reference 97.
Added Glantz et al. as reference 18.
Added text to state that similar response rates in relapsing patients were seen for the histone deacetylase inhibitor ramidepsin for 130 evaluable patients in a prospective trial (cited Coiffler et al. as reference 70).
Added Di Sabatino et al. as reference 87.
Added Bazarbachi et al. as reference 125.
Added Griffiths et al. as reference 143.
Added LaCasce et al. as reference 144.
Stage Information for Adult NHL
Revised text to state that interim positive emission tomography (PET) scans after two to four cycles of therapy did not provide reliable prognostic information because of problems of interobserver reproducibility in a large cooperative group trial, ECOG-E3444, and lack of difference in outcome between PET-negative and PET-positive/biopsy-negative patients in two prospective trials (cited Pregno et al. as reference 9).
Added Salles et al. and Advani et al. as references 13 and 14, respectively.
Treatment for Indolent, Stage I and Contiguous Stage II Adult NHL
Added Kelsey et al. and Seymour et al. as references 6 and 7, respectively.
Treatment for Indolent, Noncontiguous Stage II/III/IV Adult NHL
Revised text to state that rituximab may be considered as first-line therapy, either alone or in combination with other agents.
Added text to state that in a meta-analysis of 2,586 patients with follicular lymphoma, nine randomized clinical trials compared rituximab maintenance with no maintenance and showed improved overall survival (OS) for rituximab maintenance in previously treated patients (cited Vidal et al. as reference 56 and level of evidence: 1iiA).
Added Al Khabori et al. as reference 66.
Added text to the list of treatment options under clinical evaluation to include ofatumumab, a human anti-CD20 monoclonal antibody (cited Czuczman et al. as reference 71) and short-course low-dose, palliative radiation therapy (cited Chan et al. and Rossier et al. as references 72 and 73, respectively).
Treatment for Aggressive, Stage I and Contiguous Stage II Adult NHL